In October 2025, Cygnus Bio successfully closed a new financing round raising over RMB 100 million. The round was co-led by Shunxi Fund and E-Town Capital. This financing delivers strong growth momentum for Cygnus Bio and underscores the capital market’s high recognition of the company’s technological innovation capabilities and long-term development potential.
Following the completion of this funding round, Cygnus Bio will concentrate its resources on two core strategic priorities: R&D innovation and market expansion. On the R&D front, the company will continue to invest in core gene sequencing technologies, strengthen its sustainable innovation team, accelerate the launch of application-specific gene sequencing products, and further optimize the performance of existing offerings to deliver enhanced technical support for scientific research and clinical applications. In terms of market penetration and commercialization, Cygnus Bio will deepen partnerships with industry collaborators to explore and expand broader commercial application scenarios, maximizing the commercial value of gene sequencing technology.
Driven by sustained technological progress, Cygnus Bio has successfully launched its S-series and P-series gene sequencers. Among them, the S-series GS100 and GS200 sequencers have obtained EU CE-IVDR certification. Featuring rapid testing speed, high-quality data output, and low operational costs, these systems are widely deployed in pathogen genome sequencing and infectious disease surveillance, providing robust technical support for public health authorities and customs agencies. The P-series GP1000 and GP1000X sequencing platforms deliver a single-run sequencing throughput ranging from 0.3 Tb to 40 Tb.
Dr. Zitian Chen, CEO of Cygnus Bio, commented: “As an innovative enterprise deeply rooted in the gene sequencing sector, we will take this capital injection as a catalyst to focus on three key priorities. First, we will continue to increase R&D investment to achieve breakthroughs in core areas including sequencer development and reagent & consumable innovation. Second, we will deepen ecosystem cooperation with research institutions and medical facilities to build a fully integrated closed-loop system spanning technology R&D to clinical application. Third, we will promote broader accessibility of genetic technologies, enabling more people to afford and benefit from advanced genetic testing services. Cygnus Bio firmly believes that by aligning corporate growth with public needs, we can truly realize the win-win of commercial and social value.”
Shunxi Fund noted: “We have long identified gene sequencing as a strategically important emerging sector for investment. As one of the few innovative companies in China with full-chain mastery of core gene sequencing technologies, Cygnus Bio’s independently developed sequencing platform has achieved internationally competitive performance in key indicators such as speed and cost efficiency, fully reflecting the innovation strength of China’s biotechnology enterprises.” This strategic investment is based on a comprehensive evaluation of Cygnus Bio’s technological advantages, R&D team, and business model, as well as the fund’s long-term strategic positioning. The fund looks forward to empowering Cygnus Bio through capital support, resource integration, and strategic collaboration to help the company achieve leapfrog development.
A representative from the Investment Department of E-Town Capital stated: “We have long positioned the biopharmaceutical industry as a core engine for high-quality regional economic development.” As a flagship enterprise fostered by the Beijing E-Town biopharmaceutical cluster, Cygnus Bio has achieved industrial breakthroughs in clinical diagnostics, precision medicine, and other key fields through its proprietary gene sequencing platform, setting a strong example of innovation-driven development in the Beijing E-Town area.
Moving forward, Cygnus Bio will take this financing round as a new starting point to further advance innovation across the entire gene sequencing value chain.
